Michael MacDougall
About Michael MacDougall
Michael MacDougall serves as Secretary (executive officer) of SpringWorks Therapeutics, Inc., appointed effective July 1, 2025 in connection with Merck KGaA’s acquisition; he is the SEC filing signatory for post-merger deregistration documents, including Form S-8 POS, POSASR and Form 15-12G . During 2024, SpringWorks recorded $172.0 million in net product revenue from OGSIVEO and ended the year with $461.9 million in cash, cash equivalents, and marketable securities, with management guiding a path to profitability in 1H26 . Education, age, and pre‑SpringWorks career details for MacDougall are not disclosed in company filings; Bloomberg lists him as an executive officer of SpringWorks without additional biographical detail .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| SpringWorks Therapeutics, Inc. | Secretary (executive officer) | 2025–present | Led SEC deregistration and post-merger housekeeping (signatory for S-8 POS, POSASR, Form 15) |
External Roles
- Not disclosed in company filings .
Fixed Compensation
- Base salary, target bonus %, and actual bonus for Michael MacDougall are not disclosed in SpringWorks filings. He was not a Named Executive Officer in the 2025 proxy CD&A .
Performance Compensation
- No disclosure of RSUs/PSUs, performance metrics, or incentive weightings for Michael MacDougall in proxy or 8‑K filings .
Equity Ownership & Alignment
- Post-merger, SpringWorks deregistered all unsold shares under employee equity plans and terminated offerings; the company certified termination of Exchange Act registration (Form 15). Individual public equity holdings are no longer applicable given wholly‑owned status under Merck KGaA .
- Insider trading policy prohibits hedging and pledging of company stock; pledging is expressly banned .
Employment Terms
- Appointment: Effective July 1, 2025, MacDougall was appointed as an officer (Secretary) following consummation of the Merck KGaA merger; prior officers resigned at the effective time .
- Contract details, severance/change‑of‑control terms, non‑compete/non‑solicit, garden leave, and consulting arrangements for MacDougall are not disclosed in filings .
Investment Implications
- Alignment: With SpringWorks now a wholly‑owned subsidiary, classic public pay‑for‑performance alignment and equity guideline visibility for individual officers (including MacDougall) is limited; however, company policy still prohibits hedging/pledging—reducing alignment red flags .
- Retention/Selling Pressure: As public trading ceased upon deregistration and Form 15 filing, near‑term insider selling pressure signals are moot; no Form 4 trading disclosures for MacDougall were found .
- Execution Focus: MacDougall’s role as Secretary is administrative/compliance‑oriented; 2024 operational milestones (OGSIVEO revenue $172.0M, FDA approval of GOMEKLI in Feb‑2025, cash runway to profitability 1H26) indicate company‑level execution momentum during the period surrounding his appointment, though performance attribution to him is not disclosed .